A naturopathic approach to the prevention of cardiovascular disease: cost-effectiveness analysis of a pragmatic multi-worksite randomized clinical trial

Patricia M Herman, Orest Szczurko, Kieran Cooley, Dugald Seely, Patricia M Herman, Orest Szczurko, Kieran Cooley, Dugald Seely

Abstract

Objective: To determine the cost-effectiveness of a worksite-based naturopathic (individualized lifestyle counseling and nutritional medicine) approach to primary prevention of cardiovascular disease (CVD).

Methods: Economic evaluation alongside a pragmatic, multi-worksite, randomized controlled trial comparing enhanced usual care (EUC; usual care plus biometric screening) to the addition of a naturopathic approach to CVD prevention (NC+EUC).

Results: After 1 year, NC+EUC resulted in a net decrease of 3.3 (confidence interval: 1.7 to 4.8) percentage points in 10-year CVD event risk (number needed to treat = 30). These risk reductions came with average net study-year savings of $1138 in societal costs and $1187 in employer costs. There was no change in quality-adjusted life years across the study year.

Conclusions: A naturopathic approach to CVD primary prevention significantly reduced CVD risk over usual care plus biometric screening and reduced costs to society and employers in this multi-worksite-based study. Trial Registration clinicaltrials.gov Identifier: NCT00718796.

Figures

FIGURE 1.
FIGURE 1.
Flow of participants through the study.
FIGURE 2.
FIGURE 2.
Cost-effectiveness plane for societal perspective.

References

    1. Centers for Disease Control and Prevention Leading causes of death. FastStats. Washington, DC: Centers for Disease Control and Prevention; 2007
    1. Statistics Canada Leading Causes of Death. Statistics Canada; 2006
    1. Public Health Agency of Canada Tracking heart disease and stroke in Canada. In: Public Health Agency of Canada, Canadian Institute for Health Information, Canadian Stroke Network, Heart and Stroke Foundation of Canada, Statistics Canada, eds. Ottawa, Ontario: Public Health Agency of Canada; 2009:132
    1. American Heart Association Heart Disease & Stroke Statistics–2010 Update. Dallas, TX: American Heart Association; 2010
    1. Kahn R, Robertson RM, Smith R, Eddy D. The impact of prevention on reducing the burden of cardiovascular disease. Diabetes Care. 2008;31:1686–1696
    1. Libby P. The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol. 2005;46:1225–1228
    1. Murray MT, Pizzorno JE. Naturopathic Medicine. In: Jonas WG, Levin JS, eds. Essentials of Complementary and Alternative Medicine. Philadelphia, PA: Lippincott Williams and Wilkins; 1999:304–321
    1. Fleming SA, Gutknecht NC. Naturopathy and the primary care practice. Prim Care Clin Office Pract. 2010;37:119–136
    1. Smith MJ, Logan AC. Naturopathy. Med Clin North Am. 2002;86:173–184
    1. Boon HS, Cherkin DC, Erro J, et al. Practice patterns of naturopathic physicians: results from a random survey of licensed practitioners in two US States. BMC Complement Altern Med. 2004;4:14.
    1. Seely D, Szczurko O, Cooley K, et al. Naturopathic medicine for the prevention of cardiovascular disease: a randomized clinical trial. Can Med Assoc J. 2013;185:E409–E416
    1. Kessler RC, Catherine Barber MPA, Beck A, et al. The World Health Organization Health and Work Performance Questionnaire (HPQ). J Occup Environ Med. 2003;45:156.
    1. Brazier J, Roberts J, Deverill M. The estimation of a preference-based measure of health from the SF-36. J Health Econ. 2002;21:271–292
    1. D'Agostino RB, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation. 2008;117:743–753
    1. Anderson KM, Odel PM, Wilson PWF, Kannel WB. Cardiovascular disease risk profiles. Am Heart J. 1991;121:293–298
    1. Briggs A, Clark T, Wolstenholme J, Clarke P. Missing... presumed at random: cost-analysis of incomplete data. Health Econ. 2003;12:377–392
    1. McKnight PE, McKnight KM, Sidani S, Figueredo AJ. Missing Data: A Gentle Introduction. New York, NY: The Guilford Press; 2007
    1. Barber JA, Thompson SG. Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med. 2000;19:3219–3236
    1. Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Boca Raton, FL: Chapman & Hall/CRC; 1994
    1. Drummond MF, Sculpher MJ, Torrance GW, O'Brien B, Stoddart GL. Methods for the Economic Evaluation of Health Care Programmes. Oxford: Oxford University Press; 2005
    1. Franco OH, der Kinderen AJ, De Laet C, Peeters A, Bonneux L. Primary prevention of cardiovascular disease: cost-effectiveness comparison. Int J Technol Assess Health Care. 2007;23:71–79
    1. Wister A, Loewen N, Kennedy-Symonds H, McGowan B, McCoy B, Singer J. One-year follow-up of a therapeutic lifestyle intervention targeting cardiovascular disease risk. Can Med Assoc J. 2007;177:859–865
    1. Finkelstein EA, Troped PJ, Will JC, Palombo R. Cost-effectiveness of a cardiovascular disease risk reduction program aimed at financially vulnerable women: the Massachusetts WISEWOMAN project. J Womens Health Gender Based Med. 2002;11:519–526
    1. Eriksson MK, Hagberg L, Lindholm L, Malmgren-Olsson E-B, Osterlind J, Eliasson M. Quality of life and cost-effectiveness of a 3-year trial of lifestyle intervention in primary health care. Arch Intern Med. 2010;170:1470–1479
    1. Tran YBL, Frial T, Miller PSJ. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins. Can J Clin Pharmacol. 2008;14:e205–e214
    1. Goetzel RZ, Long SR, Ozminkowski RJ, Hawkins K, Wang S, Lynch W. Health, absence, disability, and presenteeism cost estimates of certain physical and mental health conditions affecting U.S. employers. J Occup Environ Med. 2003;46:398–412
    1. Mills PR, Kessler RC, Cooper J, Sullivan S. Impact of a health promotion program on employee health risks and work productivity. Am J Public Health. 2007;22:45–53
    1. Brindle P, Beswick A, Fahey T, Ebrahim S. Accuracy and impact of risk assessment in the primary prevention of cardiovascular disease: a systematic review. Heart. 2006;92:1752–1759
    1. Grover SA, Hemmelgarn B, Joseph L, Milot A, Tremblay G. The role of global risk assessment in hypertension therapy. Can J Cardiol. 2006;22:606–613

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する